Company Filing History:
1 out of 1,327 
3 out of 832,843 Years Active: 2001-2012
Title: Laura Manuelidis: Innovator in Transmissible Spongiform Encephalopathies Research
Introduction
Laura Manuelidis is a prominent inventor based in New Haven, CT (US). She has made significant contributions to the field of transmissible spongiform encephalopathies (TSE), with a focus on developing high throughput assays. Her work has implications for identifying treatment protocols and vaccine candidates for diseases such as Creutzfeldt-Jakob disease (CJD).
Latest Patents
Laura Manuelidis holds 4 patents related to her innovative research. Her latest patents include the development of stable cell lines that produce the pathological form of PrP after infection with the infectious agent for CJD. These stable cell lines provide a high throughput assay to identify suitable treatment protocols and compositions. Additionally, they serve as a rich source of the infectious CJD agent and may be utilized to identify vaccine candidates. The co-culture of neuronal cells with cells tested for infection with a TSE agent also offers a high throughput method for identifying infected cells.
Career Highlights
Throughout her career, Laura has worked at Yale University, where she has been able to advance her research in TSE. Her innovative approaches have garnered attention in the scientific community, contributing to a better understanding of these complex diseases.
Collaborations
Some of her notable coworkers include David C. Ward and Peter Lichter, who have collaborated with her on various research projects.
Conclusion
Laura Manuelidis is a trailblazer in the field of transmissible spongiform encephalopathies, with her patents and research paving the way for future advancements in treatment and prevention. Her contributions continue to impact the scientific community and enhance our understanding of these critical health issues.